|
|
5-day change | 1st Jan Change | ||
|
0.0990 AUD |
-1.00% | -1.00% | -13.91% | |
April 23, 2025 at 08:03 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Next Science Says 1Q FY25 Product Sales Of $5.3M |
08:03pm |
RE |
|
Next Science Limited, 2024 Earnings Call, Feb 28, 2025 |
Feb. 27 |
|
|
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
Next Science Receives FDA Warning Letter Over Marketing Claims, Quality Issues; Shares Fall 8% |
Feb. 25 |
MT |
|
Next Science Receives FDA Warning Letter |
Feb. 24 |
RE |
|
Next Science Limited, Q4 2024 Earnings Call, Jan 23, 2025 |
Jan. 22 |
|
|
Next Science Says Former Employee Files Derivative Complaint in US Court |
Jan. 08 |
MT |
|
Next Science Limited, Q3 2024 Earnings Call, Oct 22, 2024 |
24-10-21 |
|
|
Next Science Limited, H1 2024 Earnings Call, Aug 30, 2024 |
24-08-29 |
|
|
Next Science Limited Reports Earnings Results for the Half Year Ended June 30, 2024 |
24-08-29 |
CI |
|
Next Science Limited, Q2 2024 Earnings Call, Jul 25, 2024 |
24-07-24 |
|
|
Next Science Limited Reaffirms Revenue Guidance for the Fiscal Year 2024 |
24-07-24 |
CI |
|
Next Science Secures $5 Million Loan Facility |
24-07-16 |
MT |
|
Next Science Limited – Shareholder/Analyst Call |
24-05-02 |
|
|
Next Science Product Sales Rise 19% to $5.5 Million for March Quarter |
24-04-23 |
MT |
|
Next Science Limited, Q1 2024 Earnings Call, Apr 24, 2024 |
24-04-23 |
|
|
Study Showing Benefit from Next Science’s XPERIENCE Now Published in Scientific Journal |
24-04-19 |
MT |
|
Next Science’s BLASTX Found to be Efficacious in Treating Pressure Ulcers With Therapy, Says Study |
24-04-09 |
MT |
|
Next Science Limited Announces Dan Spira, Non-Executive Director, Not Be Seeking Re-Election |
24-04-02 |
CI |
|
Next Science’s Loss Widens in 2023 Despite 89% Revenue Growth; Shares Down 7% |
24-02-27 |
MT |
|
Next Science Limited Provides Revenue Guidance for the Fiscal Year 2024 |
24-02-27 |
CI |
|
Next Science Limited, 2023 Earnings Call, Feb 28, 2024 |
24-02-27 |
|
|
Next Science Limited Reports Earnings Results for the Full Year Ended December 31, 2023 |
24-02-27 |
CI |
|
Next Science Limited – Shareholder/Analyst Call |
23-10-24 |
|
|
Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director |
23-10-23 |
CI |
NXS: Dynamic Chart
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
More about the company
Buy
Last Close Price
0.0632USD
Average target price
0.1710USD
Spread / Average Target
+170.59%
Consensus
